Mirum Pharmaceuticals, Inc. 旗下药物Azure-1和Azure-4有望在2027年向美国监管机构提交生物制剂许可申请(BLA),并计划同期实现商业化上市。
Mirum Pharmaceuticals, Inc. 旗下药物Azure-1和Azure-4有望在2027年向美国监管机构提交生物制剂许可申请(BLA),并计划同期实现商业化上市。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.